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Palliative carethe disease course. We sought to evaluate current evidence and to develop expert practice consensus to
support clinicians who have not previously encountered patients with this rare disease.
Methods: We searched the literature for guidelines and evidence to support clinical practice recom-
mendations. We surveyed CLN1 disease experts and caregivers regarding their experiences and rec-
ommendations, and a meeting of experts was conducted to ascertain points of consensus and clinical
practice differences.
Results: We found a limited evidence base for treatment and no clinical management guidelines specific
to CLN1 disease. Fifteen CLN1 disease experts and 39 caregivers responded to the surveys, and 14 experts
met to develop consensus-based recommendations. The resulting management recommendations are
uniquely informed by family perspectives, due to the inclusion of caregiver and advocate perspectives. A
family-centered approach is supported, and individualized, multidisciplinary care is emphasized in the
recommendations. Ascertainment of the specific CLN1 disease phenotype (infantile-, late infantile-, ju-
venile-, or adult-onset) is of key importance in informing the anticipated clinical course, prognosis, and
care needs. Goals and strategies should be periodically reevaluated and adapted to patients' current
needs, with a primary aim of optimizing patient and family quality of life.
© 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
CLN1 disease, or neuronal ceroid lipofuscinosis type 1 (OMIM
256730), is a rare, autosomal recessive, neurodegenerative lyso-
somal storage disorder caused by homozygous or compound het-
erozygous pathogenic variants in CLN1 encoding the palmitoyl
protein thioesterase 1 (PPT1) enzyme, resulting in deficient PPT1
production.1 CLN1 is one of 13 or more distinct neuronal ceroid
lipofuscinosis (NCL) disorders with unique genetic etiologies.2 In
the classic form of CLN1 disease, symptoms begin during infancy;
additional phenotypes have been observed with late infantile, ju-
venile, and adult onset.2 Estimated incidence ranges from 0.03 per
100,000 live births in the United Kingdom to 5 per 100,000 live
births in Finland.3-7 Prevalence estimates range from 0.03 per 1
million inhabitants in Italy to 5.4 per 1 million inhabitants in
Finland.5,7
The pathophysiology of CLN1 disease remains poorly under-
stood, but likely involves multiple cellular pathways, as PPT1 is
expressed in neurons and other cell types, within lysosomes, as
well as in extralysosomal compartments.1,8 PPT1 plays a critical role
in the catabolism of lipid-modified proteins by removing fatty acids
from cysteine residues.9 Dysfunction in the PPT1 enzyme results in
intracellular accumulation of autofluorescent lysosomal storage
material, which has several associated downstream findings,
including impaired autophagy and neuronal death in the brain and
spinal cord.10-15
The main clinical features are developmental delay, psycho-
motor regression, seizures, ataxia, movement disorders, acquired
microcephaly, visual impairment, and premature death.16 The
complex constellation of symptoms can be diagnostically chal-
lenging, and the disease course can have devastating impacts on
affected individuals and families.
Disease-modifying therapies are not presently available for
CLN1 disease, although clinical trials are being planned.17 Current
management strategies focus on symptom relief and palliative care.
Owing to disease rarity, many clinicians lack experience treating
individuals with any NCL disorder. A care guidance document has
the potential to aid clinicians in decision-making,18 providing
family support, and optimizing patient quality of life. Yet, there are
no clinical management guidelines or consensus statements spe-
cific to CLN1 disease.
Families affected by CLN1 disease led an international initiative
to develop a clinical care consensus statement based on the guid-
ance of clinicians, researchers, and patient advocates who have
direct experience with the care of patients with CLN1 disease. Most
recommendations are based on clinical experience, as there have39been few clinical trials of management interventions in CLN1 dis-
ease.19-21 Family perspectives were included in the process to
ensure that their most salient needs were addressed.
Methods
A nonprofit rare disease patient advocacy group, Taylor's Tale,
created a partnership between families and clinicians modeled, in
part, on a consensus-building process on management strategies
for CLN2 disease.22
Literature review
A comprehensive literature review relevant to CLN1 disease
management was conducted by searching Pubmed, Embase, and
Scopus. No broad management guidelines specific to CLN1 disease
were found. Eleven publications regarding management of specific
symptoms associatedwith CLN1 disease, or neurological conditions
in general, were reviewed and incorporated into consensus
development.
CLN1 disease expert survey
A 180-question online survey of CLN1 disease experts was
adapted, with permission, from a survey used for the CLN2 disease
management consensus process.22 Experts were identified based
on clinical experience, publications, and referrals. Participants were
selected to provide diversity of geography, discipline, and experi-
ence. Survey topics included experience level, testing approaches,
occurrence of core symptoms and co-morbid conditions, and
management goals and strategies.
CLN1 disease caregiver survey
A 68-question online survey of caregivers was developed, in
English and German languages, to define unmet needs and provide
family perspectives. This survey was submitted for review to the
Western Institutional Review Board, which deemed it exempt un-
der 45 CFR x 46.104(d)(2). Primary caregivers of individuals with
CLN1 disease, living or deceased, were invited to complete the
survey through collaboration with several international Batten
Disease advocacy organizations. Survey topics included age at onset
and diagnosis, symptom burden, challenges and rewards of care,
management strategies, unmet needs, support systems, and school
accommodations.
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An advisory board meeting was held on May 18 to 20, 2019.
Meeting presentations included survey results, case studies, care-
giver perspectives, and management strategies. Roundtable dis-
cussions were held to identify areas of consensus and clinical
practice differences. Simultaneous translation was available to
participants upon request.
Results
Expert survey and advisory board meeting
Fifteen experts from seven countries on four continents
completed the survey. Respondents included 10 pediatric neurol-
ogists, a neuropsychologist, a metabolic specialist, a developmental
physical therapist, a hospice nurse, and a social worker. Of these, 14
participated in the advisory board meeting. Almost all clinicians
were from institutions with well-established referral centers for
NCL disorders. Collectively, clinicians had experience caring for
and/or evaluating over 75 patients with CLN1 disease.
Caregiver survey
Forty-four surveys were completed by respondents from six
countries. Five surveys were excluded because the respondents
were not primary caregivers. Select results are presented
throughout this publication as Caregiver Survey Insights.
Consensus
Multiple phenotypes require tailored clinical management
CLN1 disease was initially described as infantile-type NCL in
1973.23,24 At that time, NCLs were classified into four types (in-
fantile [Haltia-Santavuori], late infantile [Jansky-Bielschowsky],
juvenile [Spielmeyer-Sj€ogren], and adult [Kufs] NCL) and were
differentiated based on age at symptom onset and histochemical
findings. Infantile NCL was defined by onset between age eight and
18 months and presence of autofluorescent granular osmiophilic
deposits on ultrastructural examination.25 It is now understood
that CLN1 disease is caused by pathogenic variants in CLN1 and has
multiple phenotypes. The terms infantile, late infantile, juvenile, and
adult are used for phenotype classification based on age at onset.1,25
A juvenile-onset form (variant juvenile NCL with granular osmio-
philic deposits) was recognized in 1973 and further characterized in
the early 1990s.26,27 Late infantile CLN1 disease was described in
1998, and an adult-onset form was reported in 2001.28-30
The different CLN1 disease phenotypes vary by age at onset,
order of symptom onset, rate of disease progression, and life ex-
pectancy (Table 1 and Fig 1). Thus the ages presented in Table 1 and
throughout the text are meant to serve as a general guide rather
than an absolute definition, as there are no universally accepted ageTABLE 1.
Clinical Spectrum of CLN1 Disease Phenotypes31-33









>18 months-4 years Rapid Developmental delay, early
Juvenile >4 years-early adolescence Slow Cognitive decline, seizures,
Adult Late adolescence and older Protracted Cognitive decline, depressi
40boundaries and the literature varies. In general, the later the age at
symptom onset, the more protracted the disease course.31
For children who fall on an age boundary, it can be challenging
to predict which phenotypic category is most appropriate.
There are at least 71 different disease-causing pathogenic vari-
ants in CLN1 reported to date, with strong genotype-phenotype
correlations for certain mutations.31,34 The reference sequence for
PPT1 protein variant locations (P50897) can be found at www.
uniprot.org.35 In Finland, the classic infantile-onset form occurs
almost exclusively due to a founder effect in a single pathogenic
variant p.(Arg122Trp). Common in Germany and Italy, the patho-
genic variant p.(Leu222Pro) is associated with late infantile onset;
the p.(Asp43_Gly145del) variant is shared between infantile and
late-infantile forms in both countries. In Scotland, two pathogenic
variants contribute to a founder effect in juvenile-onset disease:
p.(Thr75Pro) and p.(Leu10Ter).27,36,37 A highly truncated enzyme is
more likely to be found in patients with the severe infantile
form.38,39 By extension, absent enzyme activity is typically associ-
ated with a more severe CLN1 disease phenotype, although even
this association is not absolute,40 making it challenging to predict
phenotype based on enzyme level. Enzyme levels for adult-onset
forms of CLN1 disease can be found within the same range as late
infantile- and juvenile-onset forms.30 Siblings are likely to present
with similar phenotypes.29,30,38,41-43
Data are limited regarding the rate of neurological decline and
anticipated lifespan for each CLN1 disease phenotype. One of the
most comprehensive studies of the longitudinal course of CLN1
disease occurred in a trial of cysteamine and N-acetylcysteine.19
Nine children with severe PPT1 mutations were followed longitu-
dinally over a range of eight to 75 months. Severe neurological
impairment or vegetative state, represented by isoelectric electro-
encephalography (EEG), occurred at a mean age of 59 (S.D. 13)
months. In general, individuals with the infantile phenotype have
the most aggressive course, with age at death in the first or
second decade (published reports range from three to 12 years).
Those with the late infantile phenotype develop a severe impair-
ment phase by age six to 12 years and may survive into the second
or third decade. Those with the juvenile phenotype reach a severe
state in the third decade and typically live into the third or fourth
decade. In a recent survey, the median age of death was 9.5, 16.6,
and 27 years for infantile, late infantile and juvenile forms,
respectively.37 The degree to which lifespan is impacted in the
adult-onset phenotype is unknown.
The diversity of disease phenotypes has implications for clinical
management. Age at symptom onset influences functional impact
and perhaps quality of life, based on the developmental status of
the individual. For example, those with juvenile onset may expe-
rience greater loss in independent function than those with in-
fantile onset, who may never develop certain independent skills.
Furthermore, caregiver needs, such as assistance with lifting and
diapering, differ with an adolescent compared with an infant. An
understanding of the clinical phenotype may help caregivers and
clinicians prepare for the disease course ahead.e, hypotonia, ataxia, myoclonus, seizures, hand stereotypies, vision loss, acquired
cognitive decline, later vision loss, ataxia, myoclonus, seizures
motor decline, ataxia, spasticity, later vision loss
on, ataxia, parkinsonism, vision loss
FIGURE 1. Examples of CLN1 disease phenotypes and symptom progressions. The ages at symptom onset depicted here are derived from clinical experience and published data and
are intended to represent sample cases. The specific occurrence, order, and age at symptom onset are variable. Figure adapted from Miriam Nickel, MD.
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Early diagnosis is critical for providing optimal symptom man-
agement, minimizing complications, and connecting families to
appropriate psychosocial support and genetic counseling.44,45
Because CLN1 disease is rare and its presentation is nonspecific, it
is not uncommon for diagnosis to take two years or more.
CLN1 disease should be considered in (1) young children older
than age six months with developmental plateauing or regression,
slowed head growth, and/or newly occurring drug-resistant epi-
lepsy, especially with myoclonic seizures, and (2) school-aged
children with some combination of visual loss, dementia, or epi-
lepsy. Although incredibly rare, a CLN1 disease diagnosis could be
considered in adults with recent onset of progressive visual,
cognitive, motor, and/or behavioral abnormalities.32,33 The differ-
ential diagnosis should include other neuronal lysosomal storage
and neurodegenerative disorders with a similar age of onset.33
Testing siblings of patients with confirmed CLN1 disease may also
be discussed with families.Caregiver Survey Insights
The distribution of caregiver-reported CLN1 disease phe-
notypes was: 51% infantile, 21% late infantile, 23% juvenile,
0% adult, and 5% unspecified.
41Diagnostic algorithms for CLN1 disease vary. The approach to a
child with a suspected neurometabolic or neurodegenerative con-
dition often includes neuroimaging, EEG if seizures have occurred,
and ophthalmologic assessment. Neuroimaging in the infantile-
onset form is primarily characterized by rapid progressive volume
loss, predominantly of the hemispheres, followed by the cere-
bellum, and then the brainstem.46 In one series, incidental chronic
subdural hematomas were evident in four of nine participants.47
Photoparoxysmal response to low-frequency intermittent photic
stimulation has been described in CLN2 and CLN6 disease,48-50
although it is not clear if this is a specific feature in CLN1 dis-
ease.48 Loss of sleep spindles is also observed, particularly in early-
onset forms.51 Retinopathy is a hallmark of the NCLs. Electroreti-
nography may hold an important diagnostic clue, with early b-
wave loss and electronegative configuration being a classic finding,
followed by early extinction.52
Genotyping of CLN1 may be the first-line diagnostic at certain
centers. Additional strategies, including gene panels (epilepsy,
lysosomal storage diseases) and whole-exome sequencing, are
increasingly used first line and are often sufficient for establishing
diagnosis, as the majority of known pathogenic variants are
sequence variants. The exact frequency of large deletions and du-
plications is not well known.16,53 When results demonstrate path-
ogenic variants that have not previously been reported, or genetic
testing is not available, PPT1 enzymatic testing for diagnostic
confirmation and/or clarification should be pursued.54 When ge-
netic testing is not available or is inconclusive, electron microscopy
of skin, rectal, or conjunctival tissue may be useful for narrowing to
Caregiver Survey Insights
The first symptoms that most frequently prompted seeking
medical attention were motor delay or decline (36%), vision
decline (22%), learning delay or decline (14%), and seizures
(14%). Additional symptoms included language delay or
decline, behavior, and sleep disturbances.
FIGURE 2. Factors impacting shared decision-making and customization of care for
patients with CLN1 disease. The color version of this figure is available in the online
edition.
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Regardless of the approach, testing for CLN2 disease should be
considered (either genotyping or tripeptidyl peptidase 1 enzymatic
testing), as CLN2 disease may present similarly, and enzyme
replacement therapy is currently available in many countries.55
General goals and principles of management
Primary management goals are to minimize symptoms and
maximize quality of life for the patient and family. Decision-making
should be a clinical team-family partnership, with respect and
support for a broad range of beliefs and choices. Caregiver
empowerment is critical; there is often a high burden of home care
and significant uncertainty surrounding prognosis.56 Symptom
management includes a broad range of strategies: pharmacologic
and nonpharmacologic therapies, nutrition, psychosocial and
school support, palliative care, and hospice support. Care should be
customized to meet a variety of needs, as illustrated in Fig 2.
Management goals and interventions may evolve as the disease
progresses. Care plans should be reassessed regularly based on
disease stage and changing needs. Table 2 summarizes approaches
to common therapeutic needs. Decision-making should be guided
by the composite of benefits, risks, and impact on family and pa-
tient stress. Medication overuse should be avoided, and care plans
should not be overly burdensome. Modifications to accommodate
functional impairment should be applied across all settings: home,
school, social environments, public spaces, and clinical settings.
Ongoing management requires a coordinated care team
Owing to varied disease manifestations, ongoing management
often involves a multidisciplinary clinical team. Regular commu-
nication and coordination of care among providers is critical. When
needed, consultation with specialists experienced in NCLs may aid
in clarification of diagnosis, addressing specific care challenges, or
providing information about research.
Seizure management
Patients with CLN1 disease may experience multiple seizure
types, including focal seizures (with or without impaired aware-
ness, with or without evolution to bilateral convulsive activity) and/
or primary generalized seizures (most often myoclonic, and also
myoclonic-atonic, tonic-clonic, atonic, tonic, or absence). General-
ized tonic-clonic seizures are less common in the infantile pheno-
type than in the juvenile phenotype.57 Seizure semiology typically
changes over time, and myoclonic seizures become prominent.33
Seizure frequency often depends on the stage of the disease, with
numerous daily seizures earlier in the disease course and few to
none later, when the EEG shows diffuse suppression, due to cortical
degeneration.58 Seizures present relatively early in the infantile
phenotype, typically between ages 14 to 36 months, following
slowed head growth, hypotonia and developmental plateauing or42regression, and often preceding visual loss.57,58 In later-onset phe-
notypes, epilepsy typically begins several years after the initial
symptom of visual impairment, following developmental regres-
sion and behavior changes.58,59
ASMs are generally started at the time of seizure onset, which
may precede or follow the clinical diagnosis of CLN1 disease. The
goal of seizure management is to attain sufficient seizure control to
maximize patient safety and quality of life while minimizing side
effects, particularly sedation and irritability. Achieving seizure
freedom may not be a realistic expectation, as epilepsy is drug-
resistant in nearly all cases.58 Therefore, priority should be given
to minimizing the most problematic seizures, such as prolonged or
clusters of convulsive seizures requiring rescue medication, more
severe seizure types resulting in increased risk of aspiration, and
seizures having a prolonged postictal phase. Myoclonus and brief
seizures lasting less than one minute that are not clustering or
causing other problems are often tolerated without changing ASMs.
Patient comorbidities and potential drug-drug or drug-symptom
interactions should be carefully weighed when making treatment
decisions.
Accurate identification of seizures is key, as it is not uncommon
for caregivers to mistake irritability with prominent arching and
dystonia for seizure; video can help clarify, although distinction of
epileptic from nonepileptic myoclonus even by video-EEG is chal-
lenging. Fortunately, the significant overlap in treatments for
epileptic and nonepileptic myoclonus lessens the impact of this
difficulty. The impact of seizures should be judged within the
context of the patient's functional status (e.g., drop seizures may be
more problematic for patients who are ambulatory or sit
independently).
General approaches to seizure management apply, including
initial ASM selection, ongoing reassessment, and use of rescue
medications.58,60 The need for ASM typically lessens as the disease
progresses, and it may be possible to shift patients on polytherapy
to monotherapy.58 Regularly scheduled EEGs are usually not
required for routine monitoring, although theymay be beneficial in
the evaluation of new events with uncertain etiology.
TABLE 2.
Summary of Management Strategies for CLN1 Disease
Domain Recommendations
Epilepsy  Apply general principles of epilepsy management
- Accurately identify seizures
- Introduce optimal ASM based on seizure type
- Explore non-drug epilepsy therapies (e.g., ketogenic diet) as appropriate
 Complete seizure freedom is often not attainable
- Balance reduction in seizure frequency and severity against potential side effects of ASMs
- Myoclonic or other brief seizures that have limited impact on QOL may not require medication adjustment
 Regularly assess ongoing benefit of specific ASMs and wean if ineffective
 Seizures may become less problematic over time
Movement disorders  Focus treatment on movement disorders that result in functional impairment
 Evaluate potential sources of movement disorders (drug side effect versus intrinsic disease symptom)
Physical, occupational, and
complementary therapies
 Initiate occupational, physical, and speech therapy early in disease course
 Provide adaptive devices and feeding therapy to maintain function and independence, as disease progresses
 Focus on range of motion and positioning needs toward end of life
Nutritional needs, gastrointestinal  Assess for nutritional needs and swallowing dysfunction or aspiration risk as motor decline ensues
 Provide nutritional supports, modified diets, and/or alternate routes of feeding as needed
Respiratory/infection management  Maintain typical childhood vaccination schedule
 Screen periodically for aspiration risk
Sleep disturbance  Maintain positive sleep hygiene practices
 Match pharmacologic strategies to the nature of the sleep disturbance
Vision  In later-onset phenotypes, obtain optimal refraction correction, aids, and vision or mobility therapies to accommodate visual
impairment
Mood and behavioral symptoms  Consider whether concomitant medications are worsening mood and behavioral symptoms
 Consider input from a behavioral/developmental disabilities specialist to identify triggers and potential modifications to
environment, routine, or interactions
Neurocognitive assessment and
educational strategies
 Assess developmental/cognitive function as appropriate for age/phenotype and needs of the child
 Classroom placement and instructional approach should match the child's needs and educational goals
 Flexibility is needed as child's school support requirements may change as disease progresses
Family support  Provide patient group peer support opportunities
 Educate about ancillary needs of families throughout disease course including sibling needs
 Reassess continually
Palliative care and end-of-life
considerations
 The earlier the disease onset, the sooner palliative care integration may be appropriate
Abbreviations:
ASM ¼ Antiseizure medication
QOL ¼ Quality of life
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are prolonged or cluster. Recommended first- and second-line
therapies for myoclonic and convulsive seizures in CLN1 disease,
based on clinical experience, are listed in Table 3. Drug availability
may vary by country.
In general, broad-spectrum ASMs should be prioritized over
sodium channel blockers, which may exacerbate myoclonus.62
However, if effective and tolerated, sodium channel blockers
should not be discontinued in patients already taking them.
Furthermore, carbamazepine, oxcarbazepine, or phenytoin may be
considered for treatment of refractory focal seizures without
prominent myoclonus. Patients should be closely observed for side
effects, such as myoclonus, irritability, crying, sleep disorders, or
regression.
Interest in cannabidiol (CBD) among caregivers is common,
stemming from development of pharmaceutical-grade CBD for
Lennox-Gastaut syndrome and Dravet syndrome, anecdotal evi-
dence, and growing general availability. Quality control concernsCaregiver Survey Insights
The majority of caregivers (72%) think the interventions
they use help improve their child's quality of life. The in-
terventions used by the greatest number of families include
antiseizure medications (ASMs), physical therapy, mas-
sage, home/school modifications, and dietary changes. A
total of 19 different interventions were reported.
43arise in the setting of self-treatment using unregulated products.
Clinicians shouldmaintain open dialoguewith caregivers regarding
use without a prescription in case adverse events or drug-drug
interactions occur due to CBD or contaminants.
Nonpharmaceutical options may be effective for intractable
seizures. Three experts had experience overseeing use of the
ketogenic diet in CLN1 disease and reported positive results with
some, but not all, patients. There are no published reports on the
efficacy or safety of the vagus nerve stimulator in CLN1-related
epilepsy. In other drug-resistant childhood epilepsies, vagus
nerve stimulation may provide modest seizure reduction and the
option to disrupt seizures without the use of rescue medication.63
However, there are several challenges related to device use,
including size, exacerbation of dysphagia and drooling, and need
for placement under general anesthesia. This intervention should
be considered only in highly intractable cases of CLN1 disease
having few remaining alternatives for seizure control.
Management of movement disorders
Many different movement disorders can occur in patients with
CLN1 disease, including myoclonus, ataxia, dystonia, chorea,Caregiver Survey Insights
Seizures and motor delay/decline are the symptoms that
worry caregivers the most (24% and 26% of responses).
Caregiver Survey Insights
Caregivers expect some amount of sedation to achieve
better seizure control, but most prioritize maintaining
alertness and the ability to interact over controlling
seizures.
Caregiver Survey Insights
Ketogenic diet had been tried in two patients. Respondents
said there was “significant seizure control” and “increased
alertness,” but “maintaining stable ketosis was difficult to
manage.”
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varies slightly by phenotype, with myoclonus characteristic of in-
fantile and late infantile forms, parkinsonism more common in
juvenile and adult forms, and ataxia occurring in all forms.19 Chorea
has been described in infantile-onset disease, but it is an infrequent
occurrence.64
The goals of treatment are to maintain function and quality of
life, prevent pain and rhabdomyolysis, and maintain range of mo-
tion and posture. Medications should be selected based on the type
of movement disorder and the impact of side effects in relation to
quality of life. Recommended medications are listed in Table 4.
Ataxia is not responsive to currently available medications. Care-
givers should be directed to develop adaptive strategies to
accommodate ataxia, using physical and occupational therapy,
adaptive equipment and technology, and visual rehabilitation.
Neurocognitive assessment and educational strategies
Patients with CLN1 disease experience progressive cognitive
decline, ultimately resulting in significant regression of cognitive
and language skills.40,43,65 Individuals with infantile and late in-
fantile phenotypes may first exhibit delays in early developmental
milestones, whereas those with juvenile onset typically experience
problems with attention and concentration, processing speed,
memory, reading, and writing.19,29,40,42,43,66,67
Individuals with CLN1 disease should undergo assessments of
cognition or development (as appropriate for age and develop-
mental level) and adaptive function upon diagnosis to establish
understanding of baseline function. These evaluations help to
create reasonable expectations based on individuals' current ca-
pabilities and inform educational and support services. Children
with a rapidly progressing infantile-onset phenotype may not
require extensive testing, and the assessment should consider
anticipation and management of emerging symptoms over aTABLE 3.
Recommended Antiseizure Medications for Use in CLN1 Disease, Per Clinical Experience
Myoclonic Seizures Convulsive S













Sodium channel blockers,k vigabatrin
* In some countries, including the United Kingdom, female patients of childbearing p
placed on birth control due to potential teratogenicity.
y Use with caution; may adversely affect language and speech.
z Lamotrigine may increase myoclonic seizures but is not contraindicated.
x For patients on clobazam cotherapy, the dose of clobazam should be reduced and th
levels of both clobazam and its active metabolite, norclobazam.61
k Sodium channel blockers should be avoided if myoclonic seizures are prominent, as
44relatively short timeline. Repeat testing for individuals with the
juvenile or adult phenotype is recommended when new cognitive
concerns arise or existing cognitive symptoms or adaptive skills
worsen.68
Selection of tests can be guided by work in other rare diseases
that result in pediatric-onset dementia.69 It is important to monitor
changes in both age-corrected test scores, which are benchmarked
against performance by typically developing children, and “raw
scores,” which describe an individual child's change over time in
relation to their own past performance on the same test. Children
with greater disease burden may need indirect assessment via
observational tools and parent/caregiver proxy report mea-
sures.70,71 Finally, evaluations should be selected with consider-
ation for the extent of vision loss.
Educational approaches should consider a pediatric dementia
model in which children may not acquire skills at the expected rate
for their age, may reach an early plateau in their maximum
attainment of skills, and will ultimately lose skills. Thus, bench-
marks for successmay focus onmaintenance of existing skills to the
degree possible, and/or support to remain engaged in the school
environment despite regression. School-based goals may include
one or more of the following: academic skills development, opti-
mizing quality of life, social and community engagement, response
to developmental delays or regression, management of challenging
behaviors, supportive care, and offering daytime respite hours to
parents and caregivers.
Existing resources from other complex neurological conditions
may be leveraged to develop educational plans for patients with
CLN1 disease, including guides produced by the Niemann-Pick
Disease Group, Rettsyndrome.org, the MPS Society, and Genetic
Education Materials for School Success.72-75 A published approach
to educational and social supports for patients with CLN3 disease









Sodium channel blockersk (carbamazepine, oxcarbazepine phenytoin)
Topiramatey
Zonisamide
otential taking valproic acid are required to undergo pregnancy monitoring and be
e patient carefully monitored for excessive sedation, as cannabidiol increases blood
they can exacerbate myoclonus.
Caregiver Survey Insights
“Motor delay or decline” and “vision decline” were ranked
as the symptoms with the greatest unmet need for thera-
peutic intervention (one-third of respondents).
Caregiver Survey Insights
Two-thirds of respondents completely or somewhat agree
with the statement, “I feel my child is welcomed at his/her
school, and that the school has partnered with me to
accommodate his/her needs.”
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Vision loss is a hallmark symptom of NCL disorders. In infantile-
onset disease, severe visual impairment occurs as early as age one
to two years due to optic atrophy and retinal degeneration. On
ophthalmic examination, atrophic optic discs, retinal hypo-
pigmentation, narrow vessels, and severely reduced electroreti-
nogram responses are reported.77 Ocular motility disturbances are
thought to be secondary to diminished vision. Reduced vision can
be the presenting symptom in the later-onset phenotypes, along
with degenerative findings on the retina or pale optic nerve
heads.30,43,78,79 Progression to extinguished electroretinogram
response occurred inmost by 60months (range 37 to 71months) in
one study of nine children with infantile-onset CLN1 disease.19
Those with later-onset phenotypes may benefit from refraction
correction (i.e., glasses), adaptive strategies for visual impairments
(e.g., braille reading), or orientation and mobility interventions.
Unfortunately, no specific interventions are currently available to
treat visual pathway degeneration.TABLE 4.






Other motor-related considerations (e.g., spasticity)
* Not available in the United States.
y Use with caution in patients with dementia.
z Only if life threatening.
45Physical, occupational, and speech therapy
Conventional approaches, such as physical, occupational, and
speech/language therapy, should comprise the core of treatment of
motor and language dysfunction, starting as soon as possible post-
symptom onset.80 Physical therapy is often the initial therapy rec-
ommended for the infantile phenotype due to rapid progressive
motor loss and gross motor delay, whereas occupational and/or
speech therapies may be established earlier for the juvenile or adult
phenotypes due to the need for adaptive strategies to cope with
vision loss and loss of language and comprehension. Adjunct
therapies may include vision, aquatic, vibration, and music thera-
pies along with acupuncture, massage, and hippotherapy.22 Care
plans should account for ways that impairments in some areas lead
to deficits in others (e.g., fine motor skills and communication,
communication and behavior).
Therapy may take place across multiple settings, including the
outpatient clinic, home, and school. Caregivers should learnse, Per Clinical Experience
Valproate



















Dopamine receptor antagonists (e.g., haloperidol, risperidone)
Dopamine-depleting medications (VMAT2 inhibitors) (e.g., tetrabenazine)
Levodopa with decarboxylase inhibitor (e.g., carbidopa)













Families reported using a wide variety of adaptive devices,
including bath chairs, wheelchairs, standers, feeding chairs,
adaptive toilet chairs, lift/pulley systems, and exercise
equipment.
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evolve as functional status declines. Strength, function, and
mobility should be maintained as long as possible, specifically large
muscle group activity such as walking or crawling, while progres-
sively adapting activities of daily living to compensate for
increasing disability, including feeding, dressing, bathing, and
school performance. Eventually, as patients lose voluntary control
of muscle movement, therapy should focus onmaintaining range of
motion, spasticity management, positioning, and pain manage-
ment. Over time, sessions may shift to periodic or consultative,
while positioning and range of motion exercises are implemented
by caregivers at home. Availability and health care coverage of
these services vary greatly by country.
Adaptive and assistive devices can play an important role in
maintaining quality of life. Thosewith the juvenile- and adult-onset
forms may require assistance when ambulating, progressing from
use of a cane, to posterior or anterior walker, to gait trainer, to
wheelchair. When possible, medical, school, and home evaluations
are recommended to identify appropriate treatment, equipment,
safety supports, and adaptations for each setting.
When appropriate, speech and language therapy should be
introduced early on to optimize learning of an effective commu-
nication system before cognitive decline and to monitor for swal-
lowing and feeding needs.Nutritional, gastrointestinal, secretion, respiratory, and anesthesia
management
Motility disorders, including gastroesophageal reflux, con-
stipation, and dysphagia, are common secondary complications of
CLN1 disease. The goals of gastrointestinal symptom management
are to maintain nutritional status, minimize reflux and con-
stipation, and maximize patient comfort.22
Dysphagia increases the risk of aspiration, pneumonitis, and
secondary lung infection.22 Caregivers should be taught to recog-
nize signs of dysphagia, such as coughing and choking during
meals. Periodic observation of feeding by a speech-language
specialist is recommended, along with swallowing therapy to
maintain oral feeding as long as feasible. Diets typically require
modification based on swallowing ability and are optimized for
nutrient content and gut motility. Coordination of care with a
nutritionist can help ensure that nutritional needs are met. Some
experts recommend use of nutritional supplements, multivitamins,
and vitamin D/calcium due to high fracture risk, as well as carnitine
in patients taking valproic acid. Families may use additional sup-
plements; clinicians should regularly enquire about supplement
use to monitor for potential drug interactions or adverse effects.
Eventually, other feeding routes (typically, nasogastric or gas-
trostomy/jejunostomy tube) should be considered, as most patients
with CLN1 disease become unable tomeet nutritional requirements
through oral feeding, experience aspiration pneumonia, or
demonstrate signs of dysphagia.81 Evaluation for pharmacologic
management of secretions may also be warranted.82-84 Decision-
making around feeding should be incorporated into ongoing
palliative care discussions.Caregiver Survey Insights
Physical therapy and occupational therapy were ranked as
the most effective ways to manage CLN1 disease symp-
toms, after antiseizure medications.
46Excess secretions leading to increased aspiration risk can be
managed using positioning and suctioning techniques and/or
pharmacologic intervention. Appropriate agents include glyco-
pyrronium bromide, scopolamine patch, inhaled terbutaline, hyo-
scyamine/hyoscine butylbromide, and botulinum toxin injected
into salivary glands.
In advanced disease stages, respiratory compromise may
develop due to a combination of weakness, poor cough or airway
clearance, central or obstructive apnea, or recurrent aspiration
pneumonitis or pneumonia. Adherence to the typical recom-
mended vaccination schedule is suggested, including seasonal
influenza vaccination, given the higher-than-average risk for
complications from respiratory and other illnesses.85,86 Specific
supports are determined based on the cause(s) of respiratory
compromise and may include pulmonary hygiene (e.g., chest
physical therapy) and bronchodilators. Decisions to initiate moni-
toring or breathing support should include discussion regarding
end-of-life care with families.
Children with CLN1 disease may also be at increased risk for
episodes of hypothermia and/or sinus bradycardia during anes-
thesia and should be monitored for complications accordingly.87
Management of sleep disturbance
Nearly all patients with CLN1 disease suffer from sleep distur-
bance, including difficulty falling asleep, reduced sleep duration,
and/or night wakings.60 Sleep dysfunction in the NCLs can be
associated with seizures, pharmacotherapy, movement disorders,
and circadian rhythm disruption due to vision loss and neuro-
degeneration.88-93
Sleep disruption can impair seizure control and affect mood,
cognition, and behavior, with profound impacts on the entire
family.60,94,95 Sleep onset disorders may respond to melatonin,
whereas sleep maintenance dysfunction may not.60,96,97 If snoring
is present, an overnight polysomnogram should be considered to
evaluate for sleep-disordered breathing. Restless legs syndrome
can occur, responsive to iron supplementation for low ferritin
levels.98,99 In the absence of any known cause, off-label use of
medications like clonidine, gabapentin, pregabalin, or benzodiaz-
epines may be considered.100 One clinician reported success with
levomepromazine and nitrazepam for children with the infantile
phenotype. However, there is high variability in the types of sleep
disturbances experienced by patients and lack of consistent success
with any single approach to strongly recommend a specific strat-
egy. Families may benefit from working with a sleep specialist toCaregiver Survey Insights
Caregivers reported using different supplements, including
multivitamins, melatonin, levocarnitine, N-acetylcysteine,
microalgae, apigenin, coQ10, curcumin, CBD oil, tetrahy-
drocannabinol, vitamin C, vitamin B complex, and fiber.
Caregiver Survey Insights
91% of caregiver respondents reported sleep disturbance
among patients. The symptoms most frequently reported
were trouble staying asleep/night waking and trouble fall-
ing asleep.
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positive sleep hygiene practices.
Management of pain and distress
Assessment of pain in CLN1 disease can be challenging due to
lost verbal communication, yet appropriate treatment is essential
to optimal quality of life. CLN1 disease is associated with multiple
symptoms that may be misinterpreted as pain and distress,
particularly myoclonus, spasticity, opisthotonos, crying, screaming,
hypersalivation, tachycardia, tachypnea, and sweating. Suspected
pain hasmany possible etiologies, such as dystonia, gastrointestinal
discomfort, injury, fracture, and reduced mobility. A systematic
review of possible causes of pain (Table 5) can help caregivers
differentiate clinical pain from other physical manifestations and
allow the root cause to be addressed.
For clinical assessment of pain, most experts rely on appearance
and family accounts, with some using vital signs and pain scales.
Many of the pain assessments used in the general pediatric popu-
lation are not well-suited for individuals with visual and commu-
nication impairments combined with motor and cognitive
dysfunction. Scales that may be useful before loss of communica-
tion in older patients include the Batten observational pain scale,
Pediatric Pain Profile, and Non-Communicating Children's Pain
Checklist (NCCPC-R).101-104 Postoperative pain may be assessed
using the NCCPC-PV (postoperative version) or the revised Faces,
Leg, Activity, Cry, Consolability scale.105,106 None of these scales
have been validated for use specifically with patients with CLN1
disease, and results should be evaluated with caution.
Pain and/or distress should be managed as appropriate for
children and in accordancewith the presumed pain/distress source.
Management of mood and behavioral symptoms
A broad range of mood, behavioral, and cognitive symptoms can
occur across the various CLN1 disease phenotypes (Table 6).
Assessment of psychiatric symptoms often depends on caregiver
report; patients who are developmentally and verbally capable of
contributing to assessment should be evaluated directly. Use of
standardized child behavior questionnaires, may help ensure aTABLE 5.










Reflux, gastritis, upper gastrointestinal bleeding, constipation, concreme





Skin Lack of movement, repetitive involuntary movements
Interventions Suctioning, tube feeding, wound care
47comprehensive review of all potentially concerning symptoms.
Regardless of direct patient involvement, evaluation of anxious or
sad mood should always include soliciting caregiver report of
crying, reduced or lost appetite, stomachaches, headaches, sleep
disorders, clingy behavior, restlessness, aggression, and agitation.
Although not specific to anxiety or sadness, these symptoms are
common behavioral correlates of these internalizing symptoms.
Possible medical causes of emotional or behavioral distress should
be considered, such as aggression or irritability related to antiepi-
leptic drug use.
Management of mood and behavior varies based on the symp-
tom or clinical syndrome. Pharmacologic strategies should be tar-
geted to the primary symptom when possible. Avoid neuroleptic
drugs, if possible, due to risk of extrapyramidal side effects, espe-
cially in patients with parkinsonism. However, neuroleptic medi-
cations may be the best choice in some patients with severe
aggression and may be effective for chorea. Caregivers should
evaluate potential environmental triggers for emotional and
behavioral distress and use nonpharmacologic interventions to the
extent possible. For clinical support of children with challenging
behaviors, a functional behavioral assessment (FBA) may be used to
determine the function of patients' undesirable behaviors, identify
factors that may (intentionally or inadvertently) result in mainte-
nance of the behavior, and apply this information to the design of
positive behavioral interventions. FBAs are administered by FBA
specialists in any environment where challenging behaviors occur,
for example, school or home.109-111Other considerations
Some families will need to manage a transition of care from
pediatric to adult service providers. The transition to adult care
should be planned well in advance. Ideally, a meeting is convened
with the lead pediatric and adult care clinicians and the family to
facilitate transition. Organizations such as the Child Neurology
Foundation and the International League Against Epilepsy have
transition tools that may be applicable.112,113Palliative care and end-of-life considerations
Palliative care and hospice follow a family-centered care
approach that considers impacts on the whole family. At an
increasing number of centers, palliative care teams are integrated
from the time of diagnosis and are considered partners in the
management of complex symptoms. It should be emphasized to
parents that palliative care does not equate to focusing on end-of-
life care or limiting the scope of treatment. Rather, palliative care is
an approach to optimizing patient comfort throughout the
lifespan.Hints
on, Alleviation or worsening when moved, abnormal positions or movements,
new-onset lack of movement
nts, Nightly wakening, problems before/after feeds, weight loss, hematemesis,
anemia, stool/urine consistency/frequency, hard stools
Malodorous breath, swelling, bleeding
Pressure areas, blisters, wounds
Timing and association with specific activities
TABLE 6.
Cognitive and Behavioral Symptoms of CLN1 Disease by Phenotype29,42,43,65,66,107,108
Phenotype (Age at Initial Symptom Onset) Initial Cognitive and Behavioral Symptoms Later Cognitive and Behavioral Symptoms




Loss of motor and language milestones
Loss of social interaction





Loss of motor, speech, and language milestones
Irritability




Juvenile (>4 years to early adolescence) Poor concentration
Learning difficulties
Hyperactivity




Adult (late adolescence and older) Disorientation
Decreased verbal fluency
Poor attention and memory
Dysthymia, apathy
Dementia
Loss of motor skills and language
* Symptoms related to psychosis may include auditory and visual hallucinations, delusions, rapid mood swings, sudden episodes of fear, sudden fits of crying, and
hyperactivity.29,43,65,108
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the patient and family and to minimize pain and discomfort.
Families should be empowered to make their wishes known,
including the preferred location for death, and decision-making
should be collaborative. Hospice services may include nursing
visits, 24-hour availability, home health aides, social work, child
life, spiritual support, palliative care, and medication and equip-
ment support. Do-not-resuscitate orders and decisions to escalate
care depend on the family wishes and the patient's current state
and should be reassessed periodically. Such decisions are typically
made earlier in the disease course for infantile CLN1 disease
compared with later-onset phenotypes, due to more rapid
progression.
Common causes of death in CLN1 disease include pneumonia,
infection, and general decline. Families should be encouraged to
develop a strong social network and participate in support groups
for bereavement support. Memory-making and legacy-building can
be helpful tools to cope with impending loss.Family support
Support is essential to meeting the primary goal of CLN1 disease
management: optimizing patient and family quality of life. Families
report that coping with CLN1 disease can be emotionally traumatic
through the entire course of illness and beyond. Clinicians may
consider a trauma-informed care approach to reduce the potential
trauma of medical visits, address general distress, and provide
anticipatory guidance in a supportive manner.114 Disease prognosis,
to the degree that it is well understood, should be discussed with
families upon diagnosis and in an ongoing fashion, as new infor-
mation emerges.Caregiver Survey Insights
“Cater to the heart, cater to the senses. Everything in their
short life should make them as happy and comfortable as
possible. When vision goes, play more music and let them
listen to their favorite movies. Ask yourself, ‘Will I regret not
doing this’ and do it.”
48Community/psychosocial support should be tailored to family
needs, culture, rituals, and belief systems. Sibling needs are
particularly important to address, as their needs may be overlooked
due to the pressing needs of the patient with CLN1 disease.
Important sources of support include other families affected by NCL
disorders (including sibling-to-sibling connections), support
groups specific to Batten disease or rare diseases in general, social
workers, families' prediagnosis communities, and the entire clinical
care team.Future perspectives
Looking ahead, there is a growing pipeline of candidate disease-
modifying treatments for CLN1 disease, including small molecules,
enzyme replacement therapy, and gene replacement therapies.
These emerging approaches have been recently reviewed
comprehensively.17,115,116Conclusions
CLN1 disease is an ultrarare illness with a limited evidence base
surrounding management that can leave clinicians and caregivers
with uncertainty in clinical decision-making. Because of its broad
constellation of symptoms and multiple phenotypes, CLN1 disease
often requires individualized, multidisciplinary care. Goals and
strategies should be re-evaluated over time and adapted to pa-
tients' current needs, with a primary aim of optimizing patient and
family quality of life.
The success of this partnership between families and clinicians
in creating a clinical management consensus demonstrates the
viability of this approach. This can be a model for other rare diseaseCaregiver Survey Insights
Some caregivers reported that pediatric palliative care op-
tions are not readily available in many locations and hos-
pice providers are largely inexperienced with pediatric
cases. Additional support is needed to make families more
comfortable when things get difficult.
Caregiver Survey Insights
“The first few months are devastating. Then, if you're lucky
you have a great support system, get put in contact with the
BDSRA. It never gets easier; each day is our new normal.”
Families reported that the biggest difference is made by
having help from family/friends (18%), respite/other care-
givers (16%), connecting via social media (14%), and
outside support groups (11%), among other support
strategies.
E.F. Augustine, H.R. Adams, E. de los Reyes et al. Pediatric Neurology 120 (2021) 38e51advocacy groups to spearhead family-clinician collaborations to
share clinical experience and recommendations. Participants
demonstrated a high level of engagement, and novel insights to
advance the clinical care of CLN1 diseasewere obtained. Integration
of the family perspective into this project was unique and valuable.
Such opportunities for ongoing collaboration are transformational
to the community, with the benefits of bringing people together
and synergistic effects that have a ripple effect beyond themeeting.Acknowledgments
This project was inspired by and modeled in part after a
collaborative effort to publish management strategies for CLN2
disease. Thank you to Lauren Seilnacht and Danny Miller of
InspireBio Consulting for project management support and family
survey development; Jessica Cohen-Pfeffer, MD, for insights from
the CLN2 disease experience; Haley's Heroes Foundation and Gar-
rett the Grand Batten Fighter for providing funding support
through contributions to Taylor's Tale; the Batten Disease Support
and Research Association (BDSRA, North America and Australia/
New Zealand groups), Batten Disease Family Association (BDFA),
and NCL Gruppe Deutschland for identifying caregiver survey
participants; Sandra Lehrman, MD, for scientific consultation; Janis
Crum, JD, for legal advice; and Alejandra Rozenberg, DVM, and
Brigitte McKee for additional translation support. The authors
gratefully acknowledge the families and clinicians worldwide who
participated to make this project possible.References
1. Vesa J, Hellsten E, Verkruyse LA, et al. Mutations in the palmitoyl protein
thioesterase gene causing infantile neuronal ceroid lipofuscinosis. Nature.
1995;376:584e587.
2. Williams RE, Mole SE. New nomenclature and classification scheme for the
neuronal ceroid lipofuscinoses. Neurology. 2012;79:183e191.
3. Simpson N, Wheeler E, Pearce D. Screening, diagnosis and epidemiology of
Batten disease. Expert Opin Orphan Drugs. 2014;2:903e910.
4. Sleat DE, Gedvilaite E, Zhang Y, Lobel P, Xing J. Analysis of large-scale whole
exome sequencing data to determine the prevalence of genetically-distinct
forms of neuronal ceroid lipofuscinosis. Gene. 2016;593:284e291.
5. Santorelli FM, Garavaglia B, Cardona F, et al. Molecular epidemiology of
childhood neuronal ceroid-lipofuscinosis in Italy. Orphanet J Rare Dis. 2013;8:
19.
6. Haltia M. The neuronal ceroid-lipofuscinoses. J Neuropathol Exp Neurol.
2003;62:1e13.
7. Williams R. NCL incidence and prevalence data. In: Mole SE, Williams R,
Goebel HH, eds. The Neuronal Ceroid Lipofuscinoses (Batten Disease). Oxford:
Oxford University Press; 2011.
8. Shyng C, Macauley SL, Dearborn JT, Sands MS. Widespread expression of a
membrane-tethered version of the soluble lysosomal enzyme palmitoyl
protein thioesterase-1. JIMD Rep. 2017;36:85e92.
9. Bellizzi JJ, Widom J, Kemp C, et al. The crystal structure of palmitoyl protein
thioesterase 1 and the molecular basis of infantile neuronal ceroid lip-
ofuscinosis. Proc Natl Acad Sci U S A. 2000;97:4573e4578.
10. Cooper JD, Tarczyluk MA, Nelvagal HR. Towards a new understanding of NCL
pathogenesis. Biochim Biophys Acta. 2015;1852:2256e2261.4911. Sleat DE, Wiseman JA, El-Banna M, et al. Analysis of brain and cerebrospinal
fluid from mouse models of the three major forms of neuronal ceroid lip-
ofuscinosis reveals changes in the lysosomal proteome. Mol Cell Proteomics.
2019;18:2244e2261.
12. Nelvagal HR, Hurtado ML, Eaton SL, et al. Comparative proteomic profiling
reveals mechanisms for early spinal cord vulnerability in CLN1 disease. Sci
Rep. 2020;10:15157.
13. Nelvagal HR, Lange J, Takahashi K, Tarczyluk-Wells MA, Cooper JD. Patho-
mechanisms in the neuronal ceroid lipofuscinoses. Biochim Biophys Acta Mol
Basis Dis. 2019;31:165570.
14. Tikka S, Monogioudi E, Gotsopoulos A, et al. Proteomic profiling in the brain of
CLN1 disease model reveals affected functional modules. Neuromolecular
Med. 2016;18:109e133.
15. Sarkar C, Sadhukhan T, Bagh MB, et al. Cln1-mutations suppress Rab7-RILP
interaction and impair autophagy contributing to neuropathology in a
mouse model of infantile neuronal ceroid lipofuscinosis. J Inherit Metab Dis.
2020;43:1082e1101.
16. Mole S, Williams R. Neuronal ceroid-lipofuscinoses. In: Adam MP, Ardinger H,
Pagon RA, et al., eds. GeneReviews® [Internet]. Seattle, WA: University of
Washington; 1993-2019.
17. Kohlschütter A, Schulz A, Bartsch U, Storch S. Current and emerging treat-
ment strategies for neuronal ceroid lipofuscinoses. CNS Drugs. 2019;33:
315e325.
18. Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Clinical guidelines:
potential benefits, limitations, and harms of clinical guidelines. BMJ.
1999;318:527e530.
19. Levin SW, Baker EH, Zein WM, et al. Oral cysteamine bitartrate and N-ace-
tylcysteine for patients with infantile neuronal ceroid lipofuscinosis: a pilot
study. Lancet Neurol. 2014;13:777e787.
20. Lonnqvist T, Vanhanen SL, Vettenranta K, et al. Hematopoietic stem cell
transplantation in infantile neuronal ceroid lipofuscinosis. Neurology.
2001;57:1411e1416.
21. Selden NR, Al-Uzri A, Huhn SL, et al. Central nervous system stem cell
transplantation for children with neuronal ceroid lipofuscinosis. J Neurosurg
Pediatr. 2013;11:643e652.
22. Williams RE, Adams HR, Blohm M, et al. Management strategies for CLN2
disease. Pediatr Neurol. 2017;69:102e112.
23. Santavuori P, Haltia M, Rapola J, Raitta C. Infantile type of so-called neuronal
ceroid-lipofuscinosis. 1. A clinical study of 15 patients. J Neurol Sci. 1973;18:
257e267.
24. Haltia M, Rapola J, Santavuori P, Ker€anen A. Infantile type of so-called
neuronal ceroid-lipofuscinosis. 2. Morphological and biochemical studies.
J Neurol Sci. 1973;18:269e285.
25. Haltia M, Goebel HH. The neuronal ceroid-lipofuscinoses: a historical intro-
duction. Biochim Biophys Acta. 2013;1832:1795e1800.
26. Carpenter S, Karpati G, Wolfe LS, Andermann F. A type of juvenile cere-
bromacular degeneration characterized by granular osmiophilic deposits.
J Neurol Sci. 1973;18:67e87.
27. Mitchison HM, Hofmann SL, Becerra CH, et al. Mutations in the palmitoyl-
protein thioesterase gene (PPT; CLN1) causing juvenile neuronal ceroid lip-
ofuscinosis with granular osmiophilic deposits. Hum Mol Genet. 1998;7:
291e297.
28. Wisniewski KE, Connell F, Kaczmarski W, et al. Palmitoyl-protein thioesterase
deficiency in a novel granular variant of LINCL. Pediatr Neurol. 1998;18:
119e123.
29. Simonati A, Tessa A, Bernardina BD, et al. Variant late infantile neuronal
ceroid lipofuscinosis because of CLN1 mutations. Pediatr Neurol. 2009;40:
271e276.
30. van Diggelen OP, Thobois S, Tilikete C, et al. Adult neuronal ceroid lip-
ofuscinosis with palmitoyl-protein thioesterase deficiency: first adult-onset
patients of a childhood disease. Ann Neurol. 2001;50:269e272.
31. Mink JW, Augustine EF, Adams HR, Marshall FJ, Kwon JM. Classification and
natural history of the neuronal ceroid lipofuscinoses. J Child Neurol. 2013;28:
1101e1105.
32. Schulz A, Kohlschütter A, Mink J, Simonati A, Williams R. NCL diseases -
clinical perspectives. Biochim Biophys Acta. 2013;1832:1801e1806.
33. Nita DA, Mole SE, Minassian BA. Neuronal ceroid lipofuscinoses. Epileptic
Disord. 2016;18:73e88.
34. NCL mutation database. Available at: https://www.ucl.ac.uk/ncl-disease/ncl-
resource-gateway-batten-disease/mutation-and-patient-database/mutation-
and-patient-datasheets-0. Accessed October 23, 2019.
35. UniProtKB - P50897 (PPT1_HUMAN). Available at: https://www.uniprot.org/
uniprot/P50897; 2020. Accessed May 6, 2020.
36. Sheth J, Mistri M, Bhavsar R, et al. Batten disease: biochemical and molecular
characterization revealing novel PPT1 and TPP1 gene mutations in Indian
patients. BMC Neurol. 2018;18:203.
37. Simonati A, Nickel M, Laine M, et al. Natural History of CLN1 Disease: Results
from an International Collaborative Study. Presented at: 16th International
Conference on Neuronal Ceroid Lipofuscinoses (NCL 2018); September 12-16,
2018; London, England.
38. Das AK, Becerra CH, Yi W, et al. Molecular genetics of palmitoyl-protein
thioesterase deficiency in the U.S. J Clin Invest. 1998;102:361e370.
39. Das AK, Lu JY, Hofmann SL. Biochemical analysis of mutations in palmitoyl-
protein thioesterase causing infantile and late-onset forms of neuronal
ceroid lipofuscinosis. Hum Mol Genet. 2001;10:1431e1439.
E.F. Augustine, H.R. Adams, E. de los Reyes et al. Pediatric Neurology 120 (2021) 38e5140. Kohan R, Cismondi IA, Kremer RD, et al. An integrated strategy for the diag-
nosis of neuronal ceroid lipofuscinosis types 1 (CLN1) and 2 (CLN2) in eleven
Latin American patients. Clin Genet. 2009;76:372e382.
41. Bonsignore M, Tessa A, Di Rosa G, et al. Novel CLN1 mutation in two Italian
sibs with late infantile neuronal ceroid lipofuscinosis. Eur J Paediatr Neurol.
2006;10:154e156.
42. Perez Poyato MS, Mila Recansens M, Ferrer Abizanda I, et al. Infantile neuronal
ceroid lipofuscinosis: follow-up on a Spanish series. Gene. 2012;499:
297e302.
43. K€alvi€ainen R, Eriksson K, Losekoot M, et al. Juvenile-onset neuronal ceroid
lipofuscinosis with infantile CLN1 mutation and palmitoyl-protein thio-
esterase deficiency. Eur J Neurol. 2007;14:369e372.
44. Kliegman RM, Bordini BJ, Basel D, Nocton JJ. How doctors think: common
diagnostic errors in clinical judgment-lessons from an undiagnosed and rare
disease program. Pediatr Clin North Am. 2017;64:1e15.
45. Dozieres-Puyravel B, Nasser H, Elmaleh-Berges M, et al. Paediatric-onset
neuronal ceroid lipofuscinosis: first symptoms and presentation at diagnosis.
Dev Med Child Neurol. 2020;62:528e530.
46. Baker EH, Levin SW, Zhang Z, Mukherjee AB. MRI brain volume measurements
in infantile neuronal ceroid lipofuscinosis. AJNR Am J Neuroradiol. 2017;38:
376e382.
47. Levin SW, Baker EH, Gropman A, et al. Subdural fluid collections in patients
with infantile neuronal ceroid lipofuscinosis. Arch Neurol. 2009;66:
1567e1571.
48. Beltran L, Valenzuela GR, Loos M, et al. Late-onset childhood neuronal ceroid
lipofuscinosis: early clinical and electroencephalographic markers. Epilepsy
Res. 2018;144:49e52.
49. Specchio N, Bellusci M, Pietrafusa N, Trivisano M, de Palma L, Vigevano F.
Photosensitivity is an early marker of neuronal ceroid lipofuscinosis type 2
disease. Epilepsia. 2017;58:1380e1388.
50. Canafoglia L, Gilioli I, Invernizzi F, et al. Electroclinical spectrum of the
neuronal ceroid lipofuscinoses associated with CLN6 mutations. Neurology.
2015;85:316e324.
51. Johnson TB, Cain JT, White KA, Ramirez-Montealegre D, Pearce DA,
Weimer JM. Therapeutic landscape for Batten disease: current treatments and
future prospects. Nat Rev Neurol. 2019;15:161e178.
52. Weleber RG, Gupta N, Trzupek KM, Wepner MS, Kurz DE, Milam AH. Elec-
troretinographic and clinicopathologic correlations of retinal dysfunction in
infantile neuronal ceroid lipofuscinosis (infantile Batten disease). Mol Genet
Metab. 2004;83:128e137.
53. Mole SE, Zhong NA, Sarpong A, et al. New mutations in the neuronal ceroid
lipofuscinosis genes. Eur J Paediatr Neurol. 2001;5:7e10.
54. Adams HR, Rose K, Augustine EF, et al. Experience, knowledge, and opinions
about childhood genetic testing in Batten disease. Mol Genet Metab.
2014;111:197e202.
55. Schulz A, Ajayi T, Specchio N, et al. Study of intraventricular cerliponase Alfa
for CLN2 disease. N Engl J Med. 2018;378:1898e1907.
56. Perestelo-Perez L, Rivero-Santana A, Abt-Sacks A, et al. Patient empower-
ment and involvement in research. Adv Exp Med Biol. 2017;1031:
249e264.
57. Santavuori P, Lauronen L, Kirveskari E, Aberg L, Sainio K, Autti T. Neuronal
ceroid lipofuscinoses in childhood. Neurol Sci. 2000;21:S35eS41.
58. Mole SE, Anderson G, Band HA, et al. Clinical challenges and future thera-
peutic approaches for neuronal ceroid lipofuscinosis. Lancet Neurol. 2019;18:
107e116.
59. Santavuori P, Vanhanen SL, Autti T. Clinical and neuroradiological diagnostic
aspects of neuronal ceroid lipofuscinoses disorders. Eur J Paediatr Neurol.
2001;5:157e161.
60. Lehwald LM, Pappa R, Steward S, de Los Reyes E. Neuronal ceroid lip-
ofuscinosis and associated sleep abnormalities. Pediatr Neurol. 2016;59:
30e35.
61. Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between
clobazam and cannabidiol in children with refractory epilepsy. Epilepsia.
2015;56:1246e1251.
62. Ferlazzo E, Trenite DK, Haan GJ, et al. Update on pharmacological treatment of
progressive myoclonus epilepsies. Curr Pharm Des. 2017;23:5662e5666.
63. Wheless JW, Gienapp AJ, Ryvlin P. Vagus nerve stimulation (VNS) therapy
update. Epilepsy Behav. 2018;88S:2e10.
64. Confort-Gouny S, Chabrol B, Vion-Dury J, Mancini J, Cozzone PJ. MRI and
localized proton MRS in early infantile form of neuronal ceroid-lipofuscinosis.
Pediatr Neurol. 1993;9:57e60.
65. Khan A, Chieng KS, Baheerathan A, Hussain N, Gosalakkal J. Novel CLN1
mutation with atypical juvenile neuronal ceroid lipofuscinosis. J Pediatr
Neurosci. 2013;8:49e51.
66. Kamate M, Prashanth GP, Hattiholi V. Clinico-investigative profile of infantile
and late-infantile neuronal ceroid lipofuscinoses. Neurol India. 2012;60:
316e320.
67. Santorelli FM, Bertini E, Petruzzella V, et al. A novel insertion mutation
(A169i) in the CLN1 gene is associated with infantile neuronal ceroid lip-
ofuscinosis in an Italian patient. Biochem Biophys Res Commun. 1998;245:
519e522.
68. Sim F, Thompson L, Marryat L, Ramparsad N, Wilson P. Predictive validity of
preschool screening tools for language and behavioural difficulties: a PRISMA
systematic review. PLoS One. 2019;14(2):e0211409.5069. Delaney KA, Rudser KR, Yund BD, Whitley CB, Haslett PA, Shapiro EG. Methods
of neurodevelopmental assessment in children with neurodegenerative dis-
ease: Sanfilippo syndrome. JIMD Rep. 2014;13:129e137.
70. Radecki L, Sand-Loud N, O'Connor KG, Sharp S, Olson LM. Trends in the use of
standardized tools for developmental screening in early childhood: 2002-
2009. Pediatrics. 2011;128:14e19.
71. Saulnier C, Klaiman C. Essentials of Adaptive Behavior Assessment of Neu-
rodevelopmental Disorders. Hoboken, NJ: JW Wiley; 2018.
72. Imrie J, Jacklin E, Mathieson T. Dementia in children, teenagers, and young
adults e a guide for parents, teachers, and care professionals. Available at:
https://nnpdf.org/files/2015/10/Childhood-Dementias-US-REV-4192017.pdf.
Accessed November 23, 2019.
73. Rettsyndrome.org. Living with Rett: school. Available at: https://www.
rettsyndrome.org/for-families/living-with-rett/school/. Accessed November
23, 2019.
74. Society M. Educational support. Available at: https://www.mpssociety.org.uk/
education. Accessed October 23, 2019.
75. Network TNERG. Genetic education materials for school success. Available at:
https://www.gemssforschools.org/default. Accessed November 22, 2019.
76. Elmerskog B, Tøssebro AG, Atkinson R, et al. 16- Overview of advances in
educational and social supports for young persons with NCL disorders. Bio-
chim Biophys Acta Mol Basis Dis. 2019;1866:165480.
77. Raitta C, Santavuori P. Ophthalmological findings in infantile type of so-called
neuronal ceroid lipofuscinosis. Acta Ophthalmol. 1973;51:755e763.
78. Ramadan H, Al-Din AS, Ismail A, et al. Adult neuronal ceroid lipofuscinosis
caused by deficiency in palmitoyl protein thioesterase 1. Editorial Mater
Neurol. 2007;68:387e388.
79. Hofmann SL, Das AK, Yi W, Lu JY, Wisniewski KE. Genotype-phenotype cor-
relations in neuronal ceroid lipofuscinosis due to palmitoyl-protein thio-
esterase deficiency. Mol Genet Metab. 1999;66:234e239.
80. Johnson CC. The benefits of physical activity for youth with developmental
disabilities: a systematic review. Am J Health Promot. 2009;23:157e167.
81. Lightdale JR, Gremse DA, Section on Gastroenterology Hepatology, and
Nutrition. Gastroesophageal reflux: management guidance for the pediatri-
cian. Pediatrics. 2013;131:e1684ee1695.
82. Reddihough D, Erasmus CE, Johnson H, McKellar GM, Jongerius PH,
Institute CP. Botulinum toxin assessment, intervention and aftercare for
paediatric and adult drooling: international consensus statement. Eur J Neu-
rol. 2010;17:109e121.
83. Mato A, Limeres J, Tomas I, et al. Management of drooling in disabled patients
with scopolamine patches. Br J Clin Pharmacol. 2010;69:684e688.
84. Fairhurst CB, Cockerill H. Management of drooling in children. Arch Dis Child
Educ Pract Ed. 2011;96:25e30.
85. Havers F, Fry A, Peacock G, Finelli L. Influenza vaccination and treatment in
children with neurologic disorders. Ther Adv Vaccines. 2014;2:95e105.
86. Keren R, Zaoutis TE, Bridges CB, et al. Neurological and neuromuscular disease
as a risk factor for respiratory failure in children hospitalized with influenza
infection. JAMA. 2005;294:2188e2194.
87. Miao N, Levin SW, Baker EH, et al. Children with infantile neuronal ceroid
lipofuscinosis have an increased risk of hypothermia and bradycardia during
anesthesia. Article. Anesth Analg. 2009;109:372e378.
88. H€at€onen T, Laakso ML, Heiskala H, Alila-Johansson A, Sainio K, Santavuori P.
Bright light suppresses melatonin in blind patients with neuronal ceroid-
lipofuscinoses. Neurology. 1998;50:1445e1450.
89. Gibbon FM, Maccormac E, Gringras P. Sleep and epilepsy: unfortunate bed-
fellows. Arch Dis Child. 2019;104:189e192.
90. Driver-Dunckley ED, Adler CH. Movement disorders and sleep. Neurol Clin.
2012;30:1345e1358.
91. Gadoth N, Oksenberg A. Sleep and sleep disorders in rare hereditary diseases:
a reminder for the pediatrician, pediatric and adult neurologist, general
practitioner, and sleep specialist. Front Neurol. 2014;5:133.
92. Gadoth N, Oksenberg A. Corrigendum: sleep and sleep disorders in rare he-
reditary diseases: a reminder for the pediatrician, pediatric and adult
neurologist, general practitioner, and sleep specialist. Front Neurol. 2015;6:6.
93. Leger D, Prevot E, Philip P, et al. Sleep disorders in children with blindness.
Ann Neurol. 1999;46:648e651.
94. Gastaut H, Tassinari CA. Triggering mechanisms in epilepsy. The electro-
clinical point of view. Epilepsia. 1966;7:85e138.
95. Ben Simon E, Maron-Katz A, Lahav N, Shamir R, Hendler T. Tired and mis-
connected: a breakdown of brain modularity following sleep deprivation.
Hum Brain Mapp. 2017;38:3300e3314.
96. Williams Buckley A, Hirtz D, Oskoui M, et al. Practice guideline: treatment for
insomnia and disrupted sleep behavior in children and adolescents with
autism spectrum disorder: report of the Guideline Development, Dissemi-
nation, and Implementation Subcommittee of the American Academy of
Neurology. Neurology. 2020;94:392e404.
97. Robinson AA, Malow BA. Gabapentin shows promise in treating refractory
insomnia in children. J Child Neurol. 2013;28:1618e1621.
98. Kryger MH, Otake K, Foerster J. Low body stores of iron and restless legs
syndrome: a correctable cause of insomnia in adolescents and teenagers.
Sleep Med. 2002;3:127e132.
99. Tilma J, Tilma K, Norregaard O, Ostergaard JR. Early childhood-onset restless
legs syndrome: symptoms and effect of oral iron treatment. Acta Paediatr.
2013;102:e221ee226.
E.F. Augustine, H.R. Adams, E. de los Reyes et al. Pediatric Neurology 120 (2021) 38e51100. Beck SE, Marcus CL. Pediatric polysomnography. Sleep Med Clin. 2009;4:
393e406.
101. Breau LM. Non-communicating children's pain checklist: better pain assess-
ment for severely disabled children. Expert Rev Pharmacoecon Outcomes Res.
2003;3:327e339.
102. Hunt A, Goldman A, Seers K, et al. Clinical validation of the paediatric pain
profile. Dev Med Child Neurol. 2004;46:9e18.
103. Barney CC, Hoch J, Byiers B, Dimian A, Symons FJ. A case-controlled investi-
gation of pain experience and sensory function in neuronal ceroid lip-
ofuscinosis. Clin J Pain. 2015;31:998e1003.
104. Barney CC, Feyma T, Beisang A, Symons FJ. Pain experience and expression in
Rett syndrome: subjective and objective measurement approaches. J Dev Phys
Disabil. 2015;27:417e429.
105. Breau LM, Finley GA, McGrath PJ, Camfield CS. Validation of the non-
communicating children's pain checklist-postoperative version. Anesthesi-
ology. 2002;96:528e535.
106. Malviya S, Voepel-Lewis T, Burke C, Merkel S, Tait AR. The revised FLACC
observational pain tool: improved reliability and validity for pain assess-
ment in children with cognitive impairment. Paediatr Anaesth. 2006;16:
258e265.
107. Niida Y, Yokoi A, Kuroda M, Mitani Y, Nakagawa H, Ozaki M. A girl with in-
fantile neuronal ceroid lipofuscinosis caused by novel PPT1 mutation and
paternal uniparental isodisomy of chromosome 1. Brain Dev. 2016;38:
674e677.51108. Ozono T, Kinoshita M, Narita A, et al. Juvenile-onset neuronal ceroid lip-
ofuscinosis (CLN1) disease with a novel deletion and duplication in the PPT1
gene. J Neurol Sci. 2018;388:4e6.
109. Resources CfPI. Behavior assessment, plans, and positive supports. Available
at: https://www.parentcenterhub.org/behavassess/. Accessed March 22, 2020.
110. Practice CfECa. Functional behavioral assessment. Available at: http://web.
archive.org/web/20161219171946/cecp.air.org/fba/. AccessedMarch 22, 2020.
111. Quinn MM, Gable R, Rutherford Jr RB, Nelson CM, Howell KW. Addressing
Student Problem Behavior. An IEP Team's Introduction to Functional Behav-
ioral Assessment and Behavior Intervention Plans. Washington, DC: The
Center for Effective Collaboration and Practice; 1998.
112. Foundation CN. Transition of care. Available at: https://www.
childneurologyfoundation.org/transitions/. Accessed February 20, 2020.
113. Epilepsy ILA. Transition in care from childhood to adult. Available at: https://
www.ilae.org/6EF4A170-BA86-11E8-B15C141877632E8F. Accessed February
20, 2020.
114. Marsac ML, Kassam-Adams N, Hildenbrand AK, et al. Implementing a trauma-
informed approach in pediatric health care networks. JAMA Pediatr.
2016;170:70e77.
115. Donsante A, Boulis NM. Progress in gene and cell therapies for the neuronal
ceroid lipofuscinoses. Expert Opin Biol Ther. 2018;18:755e764.
116. Masten MC, Mink JW, Augustine EF. Batten disease: an expert update on
agents in preclinical and clinical trials. Expert Opin Investig Drugs. 2020;29:
1317e1322.
